Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Breast Cancer
Both
Breast Cancer
Trial Information
Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study
Inclusion Criteria:
- Patients with metastatic breast cancer in first line treatment who have completed
treatment with Avastin
Exclusion Criteria:
- Patients not willing or unable to signed written consent form
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To assess the median time of treatment duration of Avastin
Outcome Time Frame:
24 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Argentina: Administración Nacional de Medicamentos, Alimentos y Tecnología Médica
Study ID:
ML25100
NCT ID:
NCT01215123
Start Date:
January 2010
Completion Date:
July 2012
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|
